Oncohematology Laboratory, Department of Woman and Child Health, University of Padova, Via Giustiniani 3, 35128, Padua, Italy.
J Neurooncol. 2014 Feb;116(3):505-13. doi: 10.1007/s11060-013-1348-3. Epub 2014 Jan 9.
5-aminolevulinic acid (5-ALA) introduction in the surgical management of Glioblastoma (GBM) enables the intra-operatively identification of cancer cells in the mass by means of fluorescence. Here, we analyzed the phenotype of GBM cells isolated from distinct tumour areas determined by 5-ALA (tumour core, 5-ALA intense and vague layers) and the potency of 5-ALA labelling in identifying GBM cells and cancer stem cells (CSCs) in the mass. 5-ALA identified distinct layers in the mass, with less differentiated cells residing in the core of the tumour. 5-ALA was able to stain up to 68.5% of CD133(+) cells in the 5-ALA intense layer and, although 5-ALA(+) cells retrieved from different tumour areas contained a similar proportion of CD133(+) cells (range 27.5-35.6%), those from the vague layer displayed the lowest ability to self-renew. In conclusion, our data demonstrate that a substantial amount of GBM cells and CSCs in the mass are able to avoid 5-ALA labelling and support the presence of heterogenic CSC populations in the GBM mass.
5-氨基酮戊酸（5-ALA）在胶质母细胞瘤（GBM）的手术治疗中的应用，使通过荧光可以在术中识别肿瘤中的癌细胞。在这里，我们分析了从通过 5-ALA 确定的不同肿瘤区域（肿瘤核心、5-ALA 强烈层和模糊层）分离出的 GBM 细胞的表型，以及 5-ALA 标记在识别肿瘤中的 GBM 细胞和癌症干细胞（CSCs）的能力。5-ALA 能够对肿瘤核心中分化程度较低的细胞进行染色。5-ALA 能够对 5-ALA 强烈层中高达 68.5%的 CD133(+)细胞进行染色，尽管从不同肿瘤区域回收的 5-ALA(+)细胞含有相似比例的 CD133(+)细胞（范围 27.5-35.6%），但来自模糊层的细胞自我更新能力最低。总之，我们的数据表明，肿瘤中大量的 GBM 细胞和 CSCs 能够逃避 5-ALA 标记，并支持 GBM 肿瘤中存在异质性 CSC 群体。
